# Real-world Dapagliflozin Treatment in Patients With Heart Failure in Portugal (EVOLUTION-HF)

> **NCT05465213** · — · COMPLETED · sponsor: **AstraZeneca** · enrollment: 283 (actual)

## Conditions studied

- Heart Failure

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05465213
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-11-28
- **Primary completion:** 2024-06-24
- **Final completion:** 2024-06-24
- **Target enrollment:** 283 (ACTUAL)
- **Last updated:** 2025-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05465213

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05465213, "Real-world Dapagliflozin Treatment in Patients With Heart Failure in Portugal (EVOLUTION-HF)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05465213. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*